A group of end-payor plaintiffs filed a request for preliminary approval of the proposed settlement Oct. 24 in the US District Court for the District of Massachusetts.
The settlement comes more than two years after a group of health and welfare funds of labor unions sued Teva, alleging it prolonged a monopoly over its brand name “QVAR” line of asthma inhalers by paying Amneal Pharmaceuticals to delay the generic version of the product. Teva acquired the rights to QVAR ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.